Duchenne Muscular Dystrophy Treatment Market to Rise at an Accelerated Pace Backed by Increasing R&D Activities in Developing Economies, states Fortune Business Insights™

 

The global duchenne muscular dystrophy treatment market size is expected to surge owing to rising drug approvals from government agencies and major products that are being developed for the treatment. Fortune Business Insights, in its latest report, titled “Duchenne Muscular Dystrophy Treatment Market Size, Share & Industry Analysis, By Treatment (Molecular Therapies, Steroid Therapy, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2019-2026.”, predicts promising growth for the market during the forecast period.

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

 

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

 

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit:

https://www.fortunebusinessinsights.com/industry-reports/duchenne-muscular-dystrophy-dmd-treatment-market-101863

Duchenne Muscular Dystrophyis primarily caused due to mutation in the DMD gene that totally disrupts the production of dystrophin, a vital protein for muscle integration. Though rare in females, DMD is most common among men across the globe. For instance, according to the National Organization for Rare Disorders (NORD), it is anticipated that about 1 in every 3,500 male births suffers from DMD globally. Medical Advancements and major drug approvals for the treatment of DMD will drive the growth of the market during the forecast period.

Request a Sample Copy of the research Report:

https://www.fortunebusinessinsights.com/enquiry/queries/duchenne-muscular-dystrophy-dmd-treatment-market-101863

What does the Report Include?

The report covers quantitative and qualitative data at the global and regional level for the anti-corrosion coatings market. Furthermore, the report provides in-depth details about the factors such as drivers and restraints, challenges, and the opportunities that the market will go through 2019 and 2026. Moreover, the report provide a comprehensive analysis of the key companies proliferating in the market, and detailed information about the strategies adopted by the companies to gain market stronghold during the projected horizon. The information is obtained by trusted sources with key insights from industry experts by our lead research analyst using several methodologies such as PESTEL analysis, SWOT analysis, and other that will contribute to the growth of the market during the forecast period.

Drivers and Restraints:

Increasing Trials for Treatment to Augur Growth

On 20^thMarch 2020, NS Pharma, a U.S.-based pharmaceutical company, announced its launch of expanded access program (EAP) to allow specific Duchenne muscular dystrophy patients in the U.S. to gain access to its vitolarsen therapy. Furthermore, NS Pharma has applied for an under priority review to the U.S. Food and Drug Administration, to seek approval of vitolarsen. The decision is expected to be passed by the U.S. FDA between July and September this year. Furthermore, scientists have reported that oral treatment using AdipoRon reduces inflammation in muscle, while it promotes muscle fiber operation, and improved motor functioning in a mice suffering from DMD. The scientists stated, “AdipoRon could pave way for developing new strategies to treat several muscle and inflammatory disorders.” Increasing clinical trials for developing cure for treating DMD is anticipated to drive the growth of the market during the forecast period.

However, high cost of the drug for the treating DMD may restrict the growth of the market during the forecast period. For instance, Eteplirsen, a drug approved by U.S. FDA for treating DMD, costs around $300,000 for an entire course that may shoot up to $750,000 annually.

Regional Analysis:

Increasing Investments for R&D Activities in Europe to Fuel Demand

Among the regions, Europe is anticipated to rise during the forecast period. This ascribable to factors such as increasing investments in R&D activities, and increasing prevalence of disease. The market in North America will witness substantial growth owing to large-scale development of products requiring government approvals for administration during the projected horizon.

On the other hand, Asia-Pacific is expected to surge during the forecast period. This is attributable to factors such as product development in countries such as Japan that will contribute to the growth of the market during the forecast period. For instance, Japan displayed the drug, DS-5141b, on the nation’s SAKIGAKE list, a designation that equals the U.S. FDA process of speedy approval of drugs.

Competitive Landscape:

Sarpeta Continuing Clinical Trials to Bode Well for Growth

Amid the ongoing havoc of global pandemic, COVID19, Sarpeta Therapeutics, in March 2020, announced its decision to ensure regular supply of Vyondys 53 (golodirsen) and Exondys 51 (eteplirsen), both which have been approved for treating DMD. Furthermore, the company continues its association with regulatory authorities to go ahead with its clinical trials. The companies operating in the market are adopting several strategies such as peoduct enhancement and development to maintain their market presence. Additionally, increasing investments in the R&D activities for the treatment of the disease to maintain market stronghold and gain major duchenne muscular dystrophy treatment market revenue will drive the growth of the market during the forecast period.

For any enquiries, please click here.

List of the Companies Operating in the Market:

·       BioMarin

·       Bristol-Myers Squibb Company

·       FibroGen, Inc.

·       Nobelpharma Co., Ltd.

·       NIPPON SHINYAKU CO. LTD.

·       Pfizer Inc.

·       SANTHERA PHARMACEUTICALS

·       Sarepta Therapeutics

·       Eli Lilly and Company

·       Among others

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping   organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.